Brendan Healy, MBChB, BSc (Hons), MRCP, FRCPath
Consultant in Microbiology and Infectious Diseases
University Hospital of Wales
BH has received educational grants and fees for consultancy from a number of pharmaceutical companies, including BMS, Gilead, Jannsenn, Abbvie, ViiV, and MSD. This is principally in work relating to hepatitis C and HIV. BH has carried out consultancy work on some antibiotics, including fidaxomicin, linezolid, tedizolid, ceftobiprole, and ceftaroline. BH declares he has no competing interests in relation to the work carried out for this topic review, Group B streptococcus.
Dr Brendan Healy would like to gratefully acknowledge Dr Susannah Froude and Dr Harriet Hughes, previous contributors to this topic.
SF declares that she has no competing interests. HH declares that she has received funds from Gilead and Biocomposites related to conference registration, travel, accommodation, and speaker fees.
William A. Petri, Jr, MD, PhD, FACP
Chief and Professor of Medicine
Division of Infectious Diseases and International Health
University of Virginia Health System
WAP declares that he has no competing interests.
James R. Hanley, MD, FAAP
Pediatric Emergency Medicine
University of Southern Alabama Children's and Women's Hospital
JRH declares that he has no competing interests.